Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cardiovascular Disease

Cardiovascular Disease

100 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cardiovascular Disease

338 trials tracked for Cardiovascular Disease: 94 in phase 3 or 4 and 44 with published results. The most-cited published study has 3236 citations.

338Trials tracked
94Phase 3 & 4
0Recruiting
44With published results
Phase distribution
Phase 4 46 Phase 3 48 Phase 2 38 Phase 1 8 Other / NA 198
  1. Phase 3 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin Completed · 3,236 cited
  2. Phase 3 PeriOperative ISchemic Evaluation-2 Trial Completed · 933 cited
  3. Phase 3 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed · 888 cited
  4. Phase 4 Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). Completed · 518 cited
  5. Phase 3 Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Completed · 477 cited
  6. Phase 3 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Completed · 430 cited
Show 44 more trials
  1. Phase 3 Secondary Prevention of Cardiovascular Disease in the Elderly Trial Completed · 314 cited
  2. Phase 3 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) Completed · 280 cited
  3. Phase 4 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed · 263 cited
  4. Phase 4 Stop Atherosclerosis in Native Diabetics Study Completed · 247 cited
  5. Phase 3 Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation Completed · 221 cited
  6. Phase 4 Reducing Total Cardiovascular Risk in an Urban Community Completed · 192 cited
  7. Phase 4 Impact of Liraglutide 3.0 on Body Fat Distribution Completed · 186 cited
  8. Phase 4 Self-Assessment Method for Statin Side-effects Or Nocebo Completed · 180 cited
  9. Phase 4 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed · 165 cited
  10. Phase 3 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Completed · 150 cited
  11. Phase 4 Vascular Inflammation in Psoriasis - Extension Study Completed · 146 cited
  12. Phase 4 Vascular Inflammation in Psoriasis Trial (The VIP Trial) Completed · 146 cited
  13. Phase 4 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men Completed · 118 cited
  14. Phase 4 Subclinical Cardiovascular Disease in Psoriatic Disease Completed · 95 cited
  15. Phase 3 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Completed · 79 cited
  16. Phase 3 A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) Completed · 66 cited
  17. Phase 4 ISCHEMIA-Chronic Kidney Disease Trial Completed · 63 cited
  18. Phase 4 COcoa Supplement and Multivitamin Outcomes Study Completed · 48 cited
  19. Phase 4 Vascular Inflammation in Psoriasis - Apremilast Completed · 44 cited
  20. Phase 3 A Trial of Tadalafil and Glycemic Traits Completed · 38 cited
  21. Phase 3 Cardiovascular Inflammation Reduction Trial Completed · 34 cited
  22. Phase 3 ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Completed · 22 cited
  23. Phase 4 Diabetes Remote Intervention to improVe Use of Evidence-based Medications Completed · 21 cited
  24. Phase 4 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed · 15 cited
  25. Phase 3 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease Completed · 15 cited
  26. Phase 3 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Completed · 15 cited
  27. Phase 3 Effect of Evolocumab on Coronary Atherosclerosis Completed · 14 cited
  28. Phase 4 Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity Completed · 12 cited
  29. Phase 3 CANVAS - CANagliflozin cardioVascular Assessment Study Completed · 11 cited
  30. Phase 3 Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support Completed · 10 cited
  31. Phase 4 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Completed · 9 cited
  32. Phase 3 Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo Completed · 8 cited
  33. Phase 4 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention Completed · 7 cited
  34. Phase 4 Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients Completed · 2 cited
  35. Phase 4 Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects Completed · 2 cited
  36. Phase 4 Phosphate Lowering in CKD Trial Completed · 2 cited
  37. Phase 4 Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients Completed
  38. Phase 3 Phone-based Intervention Under Nurse Guidance After Stroke 2 Completed
  39. Phase 4 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed
  40. Phase 4 Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Completed
  41. Phase 4 Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) Completed
  42. Phase 4 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication Completed
  43. Phase 4 CES1 Carriers in the PAPI Study Completed
  44. Phase 4 Statin Therapy for Ischemic and Nonischemic Cardiomyopathy Completed

Showing the 50 most-cited and recently-updated of 338 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Cardiovascular Disease: current evidence & treatments

Cardiovascular disease (CVD) is influenced by a variety of lifestyle and dietary factors. High consumption of ultra-processed foods (UPF) is associated with metabolic syndrome and early cardiovascular risk, particularly in children 1. Additionally, chrononutrition plays a role; eating later in the biological day or night is linked to impaired glucose regulation, reduced insulin sensitivity, and adverse cardiometabolic profiles 8. While some specific dietary components like trans fatty acids from dairy foods do not show increased cardiometabolic risk 10, other substances like Gastrodia elata polysaccharides (GEPs) may improve cardiovascular health via gut microbiota-mediated metabolic pathways 3.

Clinical management and treatment strategies vary based on patient profiles and pharmacological interventions. Multi-target therapies addressing both hypertension and dyslipidemia through various pathways (e.g., RAAS/PPAR, AMPK/SIRT1) may offer synergistic benefits 2. Specific treatments like evolocumab have shown a 29% reduction in major adverse cardiovascular events (MACE) in patients with a BMI $\ge$ 35 kg/m$^2$ 4, while oral anticoagulant (OAC) monotherapy was found to offer an optimal balance for secondary prevention in atrial fibrillation and stroke patients compared to combination strategies 24. Furthermore, pre-infection COVID-19 vaccination has been linked to lower cardiovascular and cerebrovascular event risks in individuals who subsequently contracted the virus 18.

Research highlights several gaps and emerging areas in cardiovascular care. There is a significant lack of data regarding myocardial infarction warning signs specifically for transgender and gender diverse populations, making it difficult for clinicians to provide tailored guidance 5. Additionally, medication literacy among patients with CVD is found to be low across multiple scales 6. Emerging technologies like AI-driven risk prediction show promise but face challenges regarding bias and diversity 9, while other areas such as the role of extracellular vesicles (EVs) as biomarkers face technical hurdles in clinical implementation 21.

Key drugs in the evidence

semaglutide 4 SGLT2 inhibitors 3 colchicine 2 sodium-glucose cotransporter 2 inhibitors 2 pitavastatin 2 lipid-lowering therapy 2 metformin 2 GLP-1 receptor agonists 2 rivaroxaban 2 sacubitril/valsartan 2

Latest findings

AI-generated synthesis of 12 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds home-based exercise improves VO2 peak in CVD and healthy adults
Physical Medicine & Rehab Meta-analysis
Meta-analysis finds home-based exercise improves VO2 peak in CVD and healthy adults Home Exercise Boosts Heart Health in People With and Without Cardiovascular Disease
This systematic review with meta-analysis assessed unsupervised home-based exercise programmes in healthy sedentary individuals and patients…
A meta-analysis shows unsupervised home exercise improves peak oxygen uptake in both healthy people and those with cardiovascular disease.
May 1, 2026
Lipid lowering therapy patterns in patients with ASCVD and familial hypercholesterolemia in Israel
Cardiology Cohort
Lipid lowering therapy patterns in patients with ASCVD and familial hypercholesterolemia in Israel Lipid lowering therapy patterns observed in Israeli patients
This retrospective database study examined lipid lowering therapy patterns among patients with atherosclerotic cardiovascular disease, ASCVD…
A look at how patients with high cholesterol and heart disease manage their lipid lowering therapy and treatment adherence in Israel.
Frontiers Apr 30, 2026
Systematic review of observational data shows wide variation in primary care discontinuation of lipid-lowering and antihypertensive therapies
Primary Care & Family Medicine Sys. Review
Systematic review of observational data shows wide variation in primary care discontinuation of lipid-lowering and antihypertensive therapies Millions of heart patients stop or restart key medicines at alarming rates in primary care
This systematic review of observational data analyzed 9,146,252 patients in primary care regarding discontinuation and restarting of lipid-l…
Nearly one million patients in primary care stopped or restarted heart medicines within a year, with rates varying widely by age and backgro…
medRxiv Apr 29, 2026
Systematic review of cardiovascular disease incidence in Italian adults without baseline disease
Cardiology Meta-analysis
Systematic review of cardiovascular disease incidence in Italian adults without baseline disease Heart attack and stroke risks vary wildly across Italian adults over decades
This systematic review examined the incidence of fatal and non-fatal major cardiovascular events in Italian adults aged 18 to 65 years witho…
A review of nineteen studies shows heart attack and stroke rates in Italy range from 10 per thousand per year to 46.5 per thousand over 40 y…
Frontiers Apr 29, 2026
Retrospective cohort study links ABSI and TyG index to incident cardiovascular disease in Chinese adults
Cardiology Cohort
Retrospective cohort study links ABSI and TyG index to incident cardiovascular disease in Chinese adults Combining Body Shape And Blood Sugar Predicts Heart Risk Better
This retrospective cohort study evaluated 920 overweight or obese Chinese adults aged 40 to 80 years free of cardiovascular disease at basel…
Overweight adults face higher heart risks than weight alone suggests since new measures combining body shape and blood sugar offer better cl…
Frontiers Apr 29, 2026
Umbrella review associates processed meat consumption with higher risks of cancer and chronic disease outcomes
Primary Care & Family Medicine Meta-analysis
Umbrella review associates processed meat consumption with higher risks of cancer and chronic disease outcomes Processed meat links to higher cancer and heart disease risks
This umbrella review synthesized data from 34 articles and 54 meta-analyses regarding processed meat consumption.
Eating more processed meat like bacon or hot dogs increases your risk for serious health problems including cancer and heart disease.
Frontiers Apr 28, 2026
Genome-wide analysis of 1.7 million individuals reveals shared genetic liability across cardiovascular diseases in European and East Asian biobanks
Genetics & Precision Medicine
Genome-wide analysis of 1.7 million individuals reveals shared genetic liability across cardiovascular diseases in European and East Asian biobanks Shared DNA Explains Why Heart Conditions Often Cluster Together
This genome-wide and exome-wide association analysis review synthesizes data from ~1.7 million individuals in European and East Asian bioban…
New research maps shared DNA links across eight major heart conditions, revealing how body weight and metabolism might lower genetic risk fo…
medRxiv Apr 28, 2026
Individual-participant data meta-analysis shows blood-pressure lowering reduces cardiovascular risk in CKD and non-CKD populations
Nephrology Meta-analysis
Individual-participant data meta-analysis shows blood-pressure lowering reduces cardiovascular risk in CKD and non-CKD populations Blood pressure drugs protect kidneys and hearts across all stages
This individual-participant data meta-analysis pooled results from 46 randomised trials involving 285,124 participants to evaluate…
Lowering blood pressure protects the heart and kidneys across all stages of kidney disease, but the benefit is weaker in patients who also h…
Apr 27, 2026
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Drug Pipeline Sys. Review
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Frontiers Apr 27, 2026
Cumulative LDL-C exposure strongly influences cardiovascular risk more than later-life levels
Diabetes & Endocrinology Cohort
Cumulative LDL-C exposure strongly influences cardiovascular risk more than later-life levels Lowering Cholesterol Earlier Cuts Heart Risk for Good
This perspective article discusses cardiovascular disease and familial hypercholesterolaemia.
Heart damage from high cholesterol builds slowly over decades, meaning waiting until middle age to act may already miss the best chance to p…
Frontiers Apr 27, 2026
Meta-analysis suggests Hatha yoga may improve blood pressure and glucose in non-communicable disease patients
Diabetes & Endocrinology Meta-analysis
Meta-analysis suggests Hatha yoga may improve blood pressure and glucose in non-communicable disease patients Simple Yoga Moves Could Help Manage Heart Disease Risks
This meta-analysis evaluated Hatha yoga interventions in patients diagnosed with non-communicable diseases including Type 2 Diabetes and hyp…
Adding yoga to your daily routine may lower blood pressure and blood sugar for people with sedentary lifestyles and heart risks.
Frontiers Apr 25, 2026
Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome
Drug Pipeline Sys. Review
Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome New Treatment Shifts How We Fight Heart, Kidney, and Diabetes Damage
This narrative review summarizes evidence on SGLT-2 inhibitors for patients with stages 2–4 cardiovascular-kidney-metabolic syndrome.
Maria, 58, has type 2 diabetes and high blood pressure.
Frontiers Apr 24, 2026

Questions about Cardiovascular Disease

How can oral health strategies improve care for patients with cardiovascular diseases?

Oral health strategies like screening, education, and medical-dental collaboration can improve cardiovascular care by reducing shared risk factors and inflammation.

Full answer →
Does eating processed meat increase cancer risks for people with cardiovascular diseases?

Yes, processed meat increases cancer risk for everyone, including people with cardiovascular diseases, due to shared risk factors and inflammatory pathways.

Full answer →
How does high Lipoprotein(a) relate to the severity of my coronary artery disease?

Higher Lp(a) levels are linked to more severe coronary artery disease, with a stepwise increase in Lp(a) as the number of blocked vessels rises.

Full answer →
Can liver biomarkers help predict my 10-year risk of ASCVD events in the US or China?

Yes, liver biomarkers like GGT, ALP, and globulin can improve 10-year ASCVD risk prediction in both US and Chinese populations, especially when added to traditional risk factors.

Full answer →
What lipid lowering treatments are common for ASCVD patients with familial hypercholesterolemia in Israel?

Common lipid-lowering treatments for ASCVD patients with FH in Israel include high-intensity statins, ezetimibe, and PCSK9 inhibitors, though real-world data show many patients still have uncontrolled LDL-C.

Full answer →
What do we know about extracellular vesicles causing vascular calcification in cardiovascular disease?

Extracellular vesicles (EVs) can both promote and inhibit vascular calcification in cardiovascular disease, depending on their cargo and cellular origin.

Full answer →
How does chronic air pollution specifically affect children and older adults with heart issues?

Chronic air pollution worsens heart conditions in children and older adults by triggering inflammation, oxidative stress, and vascular damage, with older adults facing higher cardiovascular mortality and children experiencing long-term developmental risks.

Full answer →
What tools help patients with cardiovascular disease understand their personal disease risk?

Risk calculators like Heart Age, along with LDL-C and blood pressure numbers, help patients with CVD understand their personal risk. Tools that show 'heart age' can motivate risk reduction.

Full answer →
See all 9 questions about Cardiovascular Disease →